Resistant mutations in CML and Ph+ALL – role of ponatinib

Overview of attention for article published in Biologics: Targets & Therapy, October 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#39 of 284)
High Attention Score compared to outputs of the same age (85th percentile)

Mentioned by

news: 1 news outlet

policy: 1 policy source

Citations

dimensions_citation: 84 Dimensions

Readers on

mendeley: 119 Mendeley

Summary News Policy documents Dimensions citations

So far, Dimensions has found 84 publications that cite this research output.

84

The most recent citing publications are shown below. View all 84 publications that cite this research output on Dimensions.

Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection

Article in Cells (April 2024)

Pre‐and post‐HSCT use of TKI therapy for fusion‐driven B‐ALL: A case series of five pediatric, adolescent and young adult patients

Article in Cancer Reports (November 2023)

Study progress of ponatinib-induced cardiovascular toxicities

Article in Adverse Drug Reactions Journal (August 2023)